research round-up |
research round-up
GREEN TEA POLYPHENOL EGCG BLUNTS ANDROGEN RECEPTOR FUNCTION IN PROSTATE CANCER
Siddiqui IA, Asim M, Hafeez BB et al. FASEB J. 2011 April; 25(4): 1198–207
prostate cancer (pCa). however, it is a temporary remission, and the patients almost inevitably develop hormone refractory prostate cancer (hrpC). hrpC is almost incurable, although most hrpC cells still express androgen receptor (Ar) and depend on the Ar for growth, making Ar a prime drug target. here, we provide evidence that epigallocatechin-3-gallate (egCg), the major polyphenol in green tea, is a direct antagonist of androgen action. in silico modeling and Fret-based competition assay showed that egCg physically interacts with the ligand- binding domain of Ar by replacing a high- affinity labeled ligand (iC50 0.4 _M). the functional consequence of this interaction was a decrease in A r - m e d i a t e d
A
ndrogen deprivAtion therApy is the major treatment for advanced
transcriptional activation, which was due to egCg mediated inhibition of interdomain n-C termini interaction of Ar. treatment with egCg also repressed the transcriptional activation by a hotspot mutant Ar (t877A) expressed ectopically as well as the endogenous Ar mutant. As the physiological consequence of Ar antagonism, egCg repressed r1881-induced pCa cell growth. in a xenograft model, egCg was found to inhibit Ar nuclear translocation and protein expression. We also observed a significant down-regulation of androgen-regulated mirnA-21 and up-regulation of a tumor suppressor, mirnA-330, in tumors of mice treated with egCg. taken together, we provide evidence that egCg functionally antagonizes androgen action at multiple levels, resulting in inhibition of pCa growth.
COMPARATIVE EFFECTIVENESS OF CLINICALLY USED LIGHT SOURCES FOR CUTANEOUS PROTOPORPHYRIN IX-BASED PHOTODYNAMIC THERAPY
Sayre RM, Dowdy JC, Gottschalk RW. J Cosmet Laser Ther. 2011 April; 13(2): 63–8
t
his report doCuMents the optical characteristics of a number of photodynamic therapy (pdt) light sources of varied types,
measured and indexed relative to estimated effectiveness
for activation of the pdt 66 ❚
c h r o m a p h o r e protoporphyrin iX (ppiX). pdt sources in use at several
May 2011 |
prime-journal.com
soft tissue disruption by liposuction, in particular if combined with time consuming, multiple procedures. early signs are non-specific and often not considered, so that diagnosis and correct management may be delayed. We report a case in which liposuction combined with other aesthetic surgical procedures caused a fat embolism syndrome in a 46-year-old woman, which was followed
F
a round-up of the most recently published academic articles and research
clinics, including intense pulsed light (ipL) sources, lasers, and continuous wave (CW) light sources, were spectroradiometrically measured and indexed relative to their overlap to an absorption spectrum of ppiX. the sources were highly disparate, varying in power from irradiance in the mW/cm2 range for the CW sources up to 30 J/cm2
per flash for
the ipL sources. our ppiX index ranged by a factor of nearly 100 (0.008–0.630) in estimated ppiX pdt effectiveness following the distinct spectral characteristics of the light sources surveyed. Application of this ppiX index, tempered with an understanding of the biology of the lesion being treated and effective spectrum of the light source reaching the lesion requiring therapy, provides a rational algorithm to approximate equivalent light doses prior to clinical protocols to establish equivalent patient outcomes employing alternative pdt light sources.
FAT EMBOLISM SYNDROME AFTER COMBINED AESTHETIC SURGERY
Erba P, Farhadi J, Schaefer DJ, Pierer G. J Plast Surg Hand Surg. 2011 February; 45(1): 51–3
At eMboLisM syndroMe is A rAre complication that develops after extended
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84